Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Bristol Myers Squibb is a global biopharmaceutical company with major positions in oncology, immunology, hematology, and cardiovascular medicine. Its latest annual reporting shows that 2025 brought a return to solid GAAP profitability after a very difficult 2024.
Quick Answer: Bristol Myers Squibb generated $48.1 billion in revenue in 2025 and reported $7.1 billion in GAAP net income attributable to Bristol Myers Squibb. For 2026, the company said it expects revenue of about $46.0 billion to $47.5 billion.
Key Bristol Myers Squibb Metrics
| Metric | Figure | Year |
|---|---|---|
| Total revenues | $48.1 billion | 2025 |
| GAAP net income attributable to BMS | $7.1 billion | 2025 |
| Employees | 34,100 | 2024 latest annual report base |
| 2026 revenue guidance | $46.0 billion to $47.5 billion | 2026 outlook |
About Bristol Myers Squibb
Bristol Myers Squibb is one of the largest pharmaceutical companies in the world and has built much of its recent scale around blockbuster medicines such as Eliquis, Opdivo, and other oncology and immunology products.
Bristol Myers Squibb Revenue Statistics
- 2025: $48.1 billion
- 2024: $48.3 billion
- 2023: $45.006 billion
- 2022: $46.159 billion
- 2021: $46.385 billion
- 2020: $42.518 billion
- 2019: $26.145 billion
- 2018: $22.561 billion
- 2017: $20.776 billion
- 2016: $19.427 billion
- 2015: $16.560 billion
- 2014: $15.879 billion
- 2013: $16.385 billion
Bristol Myers Squibb Net Earnings Statistics
- 2025: $7.1 billion
- 2024: $8.933 billion net loss
- 2023: $8.040 billion
- 2022: $6.345 billion
- 2021: $6.994 billion
- 2020: $8.995 billion net loss
- 2019: $3.460 billion
- 2018: $4.947 billion
- 2017: $975 million
- 2016: $4.507 billion
- 2015: $1.631 billion
- 2014: $2.029 billion
- 2013: $2.580 billion
2025 Update
BMS reported $48.1 billion in revenue in 2025 and $7.1 billion in GAAP net income attributable to Bristol Myers Squibb. On a non-GAAP basis, the company reported $12.5 billion in net income attributable to BMS.
2026 Update
For 2026, Bristol Myers Squibb said it expects revenue in the range of $46.0 billion to $47.5 billion. That makes 2026 one of the clearest transition years for the company as it manages product exclusivity changes while investing in new assets and pipeline growth.
Geographic Revenue Mix
BMS remains heavily weighted toward the U.S. market, and current revenue geography disclosures are more useful than the older percentage-share lines that were often repeated in older posts.
FAQ
What was Bristol Myers Squibb revenue in 2025?
BMS reported $48.1 billion in revenue in 2025.
Was Bristol Myers Squibb profitable in 2025?
Yes. BMS reported $7.1 billion in GAAP net income attributable to Bristol Myers Squibb in 2025.
How many employees does Bristol Myers Squibb have?
The latest annual report base listed 34,100 employees.
What is BMS expecting in 2026?
BMS said it expects 2026 revenue of about $46.0 billion to $47.5 billion.
Sources and References
